A combination of OSI-906 and Palbociclib (a CDK4/6 inhibitor) markedly decreased tumor growth in a PDOX model by suppressing the CDK4/6 and IGF-1R pathways (Murakami et al., 2016). This evidence concerns the gene IGF1R and neoplasm.